Additionally, given the recent demonstration that endoluminal biopsy of a bAVM can be followed by exome sequencing [74], if lesions genotyped as positive for the G12C- or G12D-activating variants in KRAS, specific inhibitors targeting these variants have been approved for treating various cancers and could be of potential use in these cases [75,76]. Here, KRAS is linked to cancer.